Abstract:T-cell prolymphocytic leukemia (T-PLL) is a rare blood cancer with poor prognosis. Overexpression of the proto-oncogene TCL1A and missense mutations of the tumor suppressor ATM are putative main drivers of T-PLL development, but so far only little is known about the existence of T-PLL gene expression subtypes. We performed an in-depth computational reanalysis of 68 gene expression profiles of one of the largest currently existing T-PLL patient cohorts. Hierarchical clustering combined with bootstrapping revealed three robust T-PLL gene expression subgroups. Additional comparative analyses revealed similarities and differences of these subgroups at the level of individual genes, signaling and metabolic pathways, and associated gene regulatory networks. Differences were mainly reflected at the transcriptomic level, whereas gene copy number profiles of the three subgroups were much more similar to each other, except for few characteristic differences like duplications of parts of the chromosomes 7, 8, 14, and 22. At the network level, most of the 41 predicted potential major regulators showed subgroup-specific expression levels that differed at least in comparison to one other subgroup. Functional annotations suggest that these regulators contribute to differences between the subgroups by altering processes like immune responses, angiogenesis, cellular respiration, cell proliferation, apoptosis, or migration. Most of these regulators are known from other cancers and several of them have been reported in relation to leukemia (e.g. AHSP, CXCL8, CXCR2, ELANE, FFAR2, G0S2, GIMAP2, IL1RN, LCN2, MBTD1, PPP1R15A). The existence of the three revealed T-PLL subgroups was further validated by a classification of T-PLL patients from two other smaller cohorts. Overall, our study contributes to an improved stratification of T-PLL and the observed subgroup-specific molecular characteristics could help to develop urgently needed targeted treatment strategies.

T-Cell Prolymphocytic Leukemia with T(x;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.

Mature T-cell Leukemia Primarily Involving Blood and Bone Marrow without TCL1 or MTCP1 Rearrangement: A Subtype of T-Prolymphocytic Leukemia or a Distinct Entity?

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment

Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia

T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement

T-cell prolymphocytic leukemia: a single-institution experience

Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemia

From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature

Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family–negative T-prolymphocytic leukemia

Anaplastic Large-Cell Lymphoma with Atypical Chromosomal Translocation T(2;5) and Hypophyseal Tumor

Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia

T-PLL Presenting with an Indolent Course

A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia

Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia

Epigenetic Alteration Contributes to the Transcriptional Reprogramming in T-cell Prolymphocytic Leukemia

TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy

Computational gene expression analysis reveals distinct molecular subgroups of T-cell prolymphocytic leukemia

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact

TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients

T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H)